Literature DB >> 34043612

HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018.

Shirley Lee Lecher, Peter Fonjungo, Dennis Ellenberger, Christiane Adje Toure, George Alemnji, Nancy Bowen, Frank Basiye, Anita Beukes, Sergio Carmona, Michael de Klerk, Karidia Diallo, Eric Dziuban, Charles Kiyaga, Henry Mbah, Johannes Mengistu, Tsietso Mots'oane, Christina Mwangi, Jane W Mwangi, Michael Mwasekaga, Jonathan N'tale, Mary Naluguza, Isaac Ssewanyana, Wendy Stevens, Innocent Zungu, Ravikiran Bhairavabhotla, Helen Chun, Nicholas Gaffga, Stephen Jadczak, Spencer Lloyd, Shon Nguyen, Ritu Pati, Katrina Sleeman, Clement Zeh, Guoqing Zhang, Heather Alexander.   

Abstract

One component of the Joint United Nations Programme on HIV/AIDS (UNAIDS) goal to end the HIV/AIDS epidemic by 2030, is that 95% of all persons receiving antiretroviral therapy (ART) achieve viral suppression.† Thus, testing all HIV-positive persons for viral load (number of copies of viral RNA per mL) is a global health priority (1). CDC and other U.S. government agencies, as part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), together with other stakeholders, have provided technical assistance and supported the cost for multiple countries in sub-Saharan Africa to expand viral load testing as the preferred monitoring strategy for clinical response to ART. The individual and population-level benefits of ART are well understood (2). Persons receiving ART who achieve and sustain an undetectable viral load do not transmit HIV to their sex partners, thereby disrupting onward transmission (2,3). Viral load testing is a cost-effective and sustainable programmatic approach for monitoring treatment success, allowing reduced frequency of health care visits for patients who are virally suppressed (4). Viral load monitoring enables early and accurate detection of treatment failure before immunologic decline. This report describes progress on the scale-up of viral load testing in eight sub-Saharan African countries from 2013 to 2018 and examines the trajectory of improvement with viral load testing scale-up that has paralleled government commitments, sustained technical assistance, and financial resources from international donors. Viral load testing in low- and middle-income countries enables monitoring of viral load suppression at the individual and population level, which is necessary to achieve global epidemic control. Although there has been substantial achievement in improving viral load coverage for all patients receiving ART, continued engagement is needed to reach global targets.

Entities:  

Year:  2021        PMID: 34043612     DOI: 10.15585/mmwr.mm7021a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  The Frequency and Predictors of Unsuppressed HIV Viral Load Among People with HIV in Nyaruguru District, Rwanda.

Authors:  François Hakizayezu; Emmanuel Biracyaza; Hosee Niyompano; Aline Umubyeyi
Journal:  HIV AIDS (Auckl)       Date:  2022-08-12

2.  An empiric tool to identify Kenyans living with HIV who will have unsuppressed viremia 18 months following treatment initiation to guide differentiated care models.

Authors:  Njambi Njuguna; Nelly Mugo; Omu Anzala; Marianne Mureithi; Elizabeth Irungu; Joyce Wamicwe; Jared M Baeten; Renee Heffron
Journal:  PLoS One       Date:  2022-07-19       Impact factor: 3.752

3.  Recent Trends in Adult and Pediatric Antiretroviral Therapy Monitoring and Failure.

Authors:  David C Boettiger; Vu Thien An; Nagalingeswaran Kumarasamy; Iskandar Azwa; Tavitiya Sudjaritruk; Khanh Huu Truong; Anchalee Avihingsanon; Jeremy Ross; Azar Kariminia
Journal:  J Acquir Immune Defic Syndr       Date:  2022-06-01       Impact factor: 3.771

4.  Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa.

Authors:  Enos Moyo; Grant Murewanhema; Godfrey Musuka; Tafadzwa Dzinamarira
Journal:  Trop Med Infect Dis       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.